on Quantum Biopharma Ltd.
Quantum Biopharma Reports Financial and Clinical Progress for 2024
Quantum Biopharma Ltd. has announced its financial results for 2024, showing a cash increase to $12.1 million USD compared to $11.1 million USD in 2023. Operating expenses dropped by over 32%, from $23.8 million USD in 2023 to $16.1 million USD. Net loss improved by 18%, reducing to $14.9 million USD from $18.2 million USD in 2023.
The clinical advancement involved a Phase 1 trial of Lucid-21-302 for multiple sclerosis, which revealed no safety concerns. The company initiated a toxicology study and is preparing an FDA submission for 2025. Strategic steps include expanding cryptocurrency holdings and dual listing on Upstream to attract a global investor base.
Corporate highlights feature the launch and growing sales of the unbuzzd dietary supplement. Additionally, a $2.5 million USD financing was closed, and collaborations anticipate market expansions in Puerto Rico and the Caribbean.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Quantum Biopharma Ltd. news